X

Trial Profile

A Phase I, safety and pharmacokinetics study of Fluorine-18-MK-6240 in Japanese subjects

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Florquinitau F18 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

22 Nov 2019 New trial record
14 Nov 2019 According to a Cerveau Technologies media release, the company announced today that the first healthy volunteer was injected and scanned in this trial. This study has received clearance from the Japanese regulatory agency, the Pharmaceutical and Medical Devices Agency (PMDA) and is being conducted at Kobe City Medical Center General Hospital.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com